Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

467
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
467
Drug Elimination: Non-Renal Routes01:23

Drug Elimination: Non-Renal Routes

2.9K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.9K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

779
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
779
Drug Elimination: The Concept of Clearance01:06

Drug Elimination: The Concept of Clearance

3.6K
Drug elimination refers to removing drugs from the body, either through urine by the kidneys or through bile by the liver. Drug clearance is a pharmacokinetic parameter that measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the plasma concentration of the drug.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital.

Drug and alcohol review·2026
Same author

Corrigendum to: Factors associated with delayed diagnosis of hepatitis B in southeastern Sydney.

Public health research & practice·2026
Same author

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.

JAMA psychiatry·2026
Same author

Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study.

The International journal on drug policy·2026
Same author

New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.

International journal of epidemiology·2026
Same author

Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysis.

The International journal on drug policy·2026

Related Experiment Video

Updated: Dec 21, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.

Marianne Martinello1, Sahar Bajis1, Gregory J Dore1

  • 1Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, Sydney, Australia.

Gastroenterology Clinics of North America
|May 12, 2020
PubMed
Summary
This summary is machine-generated.

The World Health Organization aims to eliminate hepatitis C virus (HCV) by 2030. Achieving this requires increased diagnosis and treatment, as current global rates are significantly low.

Keywords:
Direct-acting antiviralsEliminationGlobal healthHepatitis CPeople who inject drugsSustainable development goalsTreatmentUniversal health coverage

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Related Experiment Videos

Last Updated: Dec 21, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Hepatology

Background:

  • The World Health Organization has set a 2030 target for hepatitis C virus (HCV) elimination.
  • Direct-acting antiviral agents offer effective treatment options for HCV.
  • A vaccine for HCV is currently unavailable, necessitating other prevention strategies.

Purpose of the Study:

  • To outline the challenges and strategies for achieving global HCV elimination by 2030.
  • To emphasize the need for enhanced primary prevention and increased diagnosis and treatment rates.

Main Methods:

  • This study is a review of current global HCV status and elimination strategies.
  • It analyzes data on HCV diagnosis and treatment initiation rates worldwide.
  • It identifies successful country-level elimination efforts as models.

Main Results:

  • Globally, only 20% of individuals with chronic HCV are diagnosed.
  • Approximately 5% of diagnosed individuals have initiated HCV treatment.
  • Significant gaps exist in diagnosis and treatment, presenting a major hurdle to elimination.

Conclusions:

  • HCV elimination by 2030 is an ambitious but achievable goal.
  • Enhanced primary prevention, increased diagnosis, and widespread treatment are critical.
  • Successful national programs offer a viable pathway for global HCV elimination.